CB
Chengdu Brilliant Pharmaceutical at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Chengdu Brilliant Pharmaceutical brings 2 presentations to ObesityWeek 2026 in National Harbor. Its program centers on preclinical obesity drug candidates, including BPR-35000858, an ALK7-targeting siRNA that reduces adiposity with a favorable safety profile in mice and nonhuman primates. A poster covers a biased GLP-1 and amylin receptor dual agonist with a once-monthly formulation in obese rats.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
CB Chengdu Brilliant Pharmaceutical Chengdu, China | |
Drug developer with preclinical obesity programs, including an ALK7-targeting siRNA and a GLP-1/amylin dual agonist. | Talk Sat Nov 14 3:45pm–4:00pm Poster Sat Nov 14 7:30pm–8:30pm A Novel Biased GLP-1R/Amylin Receptor Dual Agonist BPR-221-008 and Once-Monthly Formulation in Obese Rats Chronic disease and obesity complications |
Find decision makers at Chengdu Brilliant Pharmaceutical
Tell us what you sell and we’ll find the people at Chengdu Brilliant Pharmaceutical most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction